BerGenBio receives positive recommendation from independent Data and Safety Monitoring Board to initiate second dose in Ph2a of BGBC016 trial Bergen, Norway, July 29, 2024, – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced today that the independent Data and Safety Monitoring Board … Read more
Bergen, Norway, 26 June 2024 – BerGenBio ASA (the “Company”) (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announce that the Board of Directors has granted options to employees. The annual general meeting in the Company on 23 May 2024 approved the share option program and … Read more
Bergen, Norway, 3 June 2024. Reference is made to the stock exchange announcement made by BerGenBio ASA (the “Company”) on 23 May 2024 regarding the Company’s annual general meeting resolving a reverse share split of the Company’s shares in the ratio 100:1. The reverse share split has today been registered with the Norwegian Register of … Read more
Issuer name: BerGenBio ASAEx. date: 30 May 2024Type of corporate action: Reverse share splitReverse split ratio: One hundred (100) old shares give one (1) new share. New par value per share: NOK 10 New ISIN: NO 001 3251173 New number of shares outstanding: 39,087,116 For further information, please contact: Martin Olin, CEO, BerGenBio ASAir@bergenbio.com Rune … Read more
Bergen, Norway, May 29, 2024 – BerGenBio ASA (OSE: BGBIO), a clinical-stage bio-pharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced financial results for the quarter ended March 31, 2024, and provided a business update. Highlights, including post period: Data Safety Monitoring Board review supported dose escalation in Ph … Read more
Bergen, Norway, May 28, 2024, – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced today that it has entered into a clinical trial agreement with the Mays Cancer Center at The University of Texas Health Science Center at San Antonio (UT Health … Read more
Bergen, Norway, 28 May 2024: Reference is made to the stock exchange announcement published by BerGenBio ASA (the “Company”) on 23 May 2023, regarding the Company’s annual general meeting resolving a reverse share split of the Company’s shares. Key information related to the reverse share split is set out below: Reverse split ratio: 100:1, i.e. … Read more
Bergen, Norway, 28 May 2024: Reference is made to the stock exchange announcement by BerGenBio ASA (the “Company”) on 23 May 2024 regarding the Company’s annual general meeting resolving to increase the Company’s share capital by NOK 3.30 by issuance of 33 new shares, each with a nominal value of NOK 0.10 to ensure that … Read more
Bergen, 23 May 2024: BerGenBio ASA held its annual general meeting today digitally through Lumi AGM. All resolutions were made in accordance with the proposals from the board of directors and the nomination committee, including, but not limited to, approval of the 2023 annual accounts, election of a member to the board of directors, the … Read more
Bergen, Norway, 22 May 2024 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors for severe unmet medical needs, will announce its results for the first quarter 2024 on Wednesday 29 May 2024. BerGenBio’s senior management team will provide a business update at 10:00 am CET. The presentation will webcast live. … Read more
soug@oncoinvent.com
Oystein Soug has over 15 years of experience in biotechnology, holding several management positions. Most recently, Mr. Soug was CEO of Arxx Therapeutics, where he led the company to initiate the clinical programme and was responsible for the merger with Dutch pharma company Oxitope Pharma to create Calluna Pharma. Prior to Arxx, he served as CFO and then CEO of Targovax, an Oslo listed biotechnology company, which went public during Mr. Soug’s tenure. Mr. Soug started his career in biotech as CFO of Oslo-listed radiopharmaceutical company Algeta. During this period, the company conducted a successful phase 3 trial, launched its radium-223 based prostate cancer drug Xofigo® and out-licensed the drug. Mr. Soug co-led the sale of the company to Bayer in 2014.
Mr. Soug holds an MSc in Economics and
Financial Markets from Universität St. Gallen in Switzerland in 1997
mansson@oncoinvent.com
Anders Månsson is a business executive with over 25 years of experience from management roles in the pharmaceutical industry, focusing on commercialisation and M&A + licensing. Mr. Månsson has held leading roles in the industry both in his native Sweden and in other European countries, and he has worked extensively with the USA and Asia as focus markets in global roles.
Mr. Månsson holds a B.Sc. degree in Business & Economics from Lund’s University in Sweden as well as an MBA from Business School Lausanne in Switzerland. He has a broad-based industrial experience, featuring both large multinational companies such as Meda, Ferring & LEO Pharma, and including leading roles in start-ups and smaller biotech companies. On top of his executive role in Oncoinvent, Mr. Månsson holds two non-executive director positions serving on the board of EQL Pharma AB as well Immetric AB, the latter being an investment company focusing on life science.